Company intelligence / Profile preview

Forma Therapeutics, Inc.

Watertown, Massachusetts, United Statesformatherapeutics.com ↗

Ownership: Private
Employees: ~176
Development stage: Other

Overview

Forma Therapeutics focused on developing treatments for sickle cell disease and other hematologic diseases. Their lead candidate, Etavopivat (FT-4202), aimed to activate PKR for SCD treatment. The company was acquired by Novo Nordisk in 2022.

Therapeutic areas: HematologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Boehringer IngelheimCelgene (now part of Bristol Myers Squibb)Janssen Pharmaceuticals

Beyond the preview

Go deeper on Forma Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forma Therapeutics, Inc..